Last edition
News about "SUNRISE Phase 3 program"
Viking Therapeutics Launches Phase 3 Trial of Oral VK2735
Viking Therapeutics has launched phase 3 trials of oral VK2735 to evaluate its efficacy in adults with obesity, with and without Type 2 Diabetes (T2D).
SUNRISE Phase 3 Program | 15/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members